Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Intestinal O2 transport and energy balance during hyperdynamic endotoxic shock in the pig: comparison of noradrenaline and NG-monomethyl-L-arginine (L-NMMA)

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Critical Care19982 (Suppl 1) :P141

https://doi.org/10.1186/cc270

  • Published:

Keywords

  • Portal Venous Blood
  • Portal Venous Blood Flow
  • Mucosal PCO2
  • Preshock Level
  • Endotoxic Shock Model

Introduction

Vasopressor therapy is current practice for treatment of arterial hypotension associated with septic shock, but may result in gut dysfunction due to intestinal vasoconstriction. Therefore we compared the effects of vasopressor treatment with the nitric oxide synthase inhibitor L-NMMA with those of noradrenaline (NOR) on intestinal O2 transport as well as energy balance in a porcine hyperdynamic endotoxic shock model.

Methods

Thirty anesthetized pigs were studied; 12 h after induction of endotoxic shock with continuous LPS infusion animals were randomly assigned to receive either no drug therapy (ETX, n = 8), or vasopressor support with noradrenaline (NOR, n = 11) or L-NMMA (L-NMMA, n = 11), respectively, in order to maintain MAP at preshock levels. Portal venous blood flow (Transonic flow probes), arterial-portal venous O2 extraction, ileal mucosal intracapillary HbO2 saturation (remission spectrophotometry EMPHO) and arterial-ileal mucosal PCO2 gaps were measured.

Results

Data are median and interquartile range. *P < 0.05 vs preshock (RM ANOVA on ranks). (See table overleaf.)

Conclusions

Despite well-preserved O2 availability neither of the two treatments could reverse the endotoxin induced derangement of intestinal energy balance.

Table

  

Preshock

12 h

18 h

24 h

Portal venous

ETX

23 (19;28)

25 (29;28)

24 (20;29)

28 (19;31)

blood flow

NOR*

23 (20;26)

25 (18;28)

36 (26;37)

38 (28;42)

(ml/min/kg)

L-NMMA

24 (22;28)

32 (24;40)

26 (23;36)

30 (19;34)

O2 extraction

ETX

34 (27;35)

29 (20;33)

26 (23;32)

26 (25;35)

(%)

NOR*

32 (26;35)

31 (27;41)

20 (18;24)

22 (1 7;32)

 

L-NMMA

31 (29;34)

31 (27;35)

31 (27;31)

31 (24;54)

ileal mucosal

ETX

43 ± 13

39 ± 21

37 ± 10

30 ± 10

intracap. HbO2

NOR

46 ± 15

44 ± 12

44 ± 8

45 ± 14

Mean ± SD

L-NMMA

48 ± 12

43 ± 11

42 ± 11

42 ± 12

Portal venous

ETX*

25.1 [22.0;29.1]

25.3 [22.5;28.5]

31.8 [22.8;34.7]

42.7 [40.0;54.5]

Lac/Pyr ratio

NOR*

28.1 [26.1 ;31.3]

31.3 [24.8;37.6]

46.4 [39.0;53.3]

44.7 [36.6;65.9]

 

L-NMMA*

20.8 [18.6;29.5]

26.5 [25.3;40.4]

39.9 [28.4;50.5]

48.0 [44.3;53.2]

ileal mucosal-

ETX*

12 (9;13)

13 (11;20)

17 (14;25)

20 (19;28)

arterial PCO2 gap

NOR*

13 (4;15)

19 (16;29)

19 (13;26)

15 (11;53)

(mmHg)

L-NMMA*

13 (11;16)

23 (17;29)

37 (13;53)

44 (28; 45)

Declarations

Acknowledgement

L-NMMA (546C88) was kindly provided by GlaxoWellcome, UK.

Authors’ Affiliations

(1)
Sektion APV, Universitätsklinik fur Anästhesiologie, D-89070 Ulm, Germany

Copyright

© Current Science Ltd 1998

Advertisement